DK1011686T3 - Modulering af human mastcelleaktivering - Google Patents

Modulering af human mastcelleaktivering

Info

Publication number
DK1011686T3
DK1011686T3 DK98917959.3T DK98917959T DK1011686T3 DK 1011686 T3 DK1011686 T3 DK 1011686T3 DK 98917959 T DK98917959 T DK 98917959T DK 1011686 T3 DK1011686 T3 DK 1011686T3
Authority
DK
Denmark
Prior art keywords
mast cell
purinoceptors
cell activation
modulation
atp binding
Prior art date
Application number
DK98917959.3T
Other languages
Danish (da)
English (en)
Inventor
Amir Pelleg
Edward B Schulman
Original Assignee
Duska Scient Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scient Co filed Critical Duska Scient Co
Application granted granted Critical
Publication of DK1011686T3 publication Critical patent/DK1011686T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
DK98917959.3T 1997-03-25 1998-03-24 Modulering af human mastcelleaktivering DK1011686T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (1)

Publication Number Publication Date
DK1011686T3 true DK1011686T3 (da) 2010-10-11

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98917959.3T DK1011686T3 (da) 1997-03-25 1998-03-24 Modulering af human mastcelleaktivering

Country Status (9)

Country Link
US (2) US6372724B1 (enExample)
EP (1) EP1011686B9 (enExample)
JP (1) JP2001518118A (enExample)
AT (1) ATE470441T1 (enExample)
AU (1) AU741713B2 (enExample)
CA (1) CA2288821C (enExample)
DE (1) DE69841711D1 (enExample)
DK (1) DK1011686T3 (enExample)
WO (1) WO1998042353A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372724B1 (en) * 1997-03-25 2002-04-16 Duska Scientific Co. Modulation of human mast cell activation
DK1187617T3 (da) 1999-06-18 2004-04-13 Alcon Mfg Ltd Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
GB9916757D0 (en) * 1999-07-17 1999-09-15 Glaxo Group Ltd Method
EP1269198A2 (en) * 2000-03-23 2003-01-02 Novartis AG Identification of mast/basophil activation inhibitors
EP1351935A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
EP1351937A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
EP1351936A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
US7378492B2 (en) * 2002-02-20 2008-05-27 Incyte Corporation CD40-related receptor that binds CD40L
WO2004015396A2 (en) * 2002-08-13 2004-02-19 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
WO2004033636A2 (en) * 2002-10-04 2004-04-22 Incyte Corporation Protein modification and maintenance molecules
WO2004044166A2 (en) * 2002-11-12 2004-05-27 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
WO2004048550A2 (en) * 2002-11-26 2004-06-10 Incyte Corporation Immune response associated proteins
US7829682B1 (en) 2003-04-30 2010-11-09 Incyte Corporation Human β-adrenergic receptor kinase nucleic acid molecule
CA2573565A1 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
EP2407484B1 (en) 2005-06-24 2016-06-22 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
WO2008113017A2 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilization of a cell and/or macromolecule
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US10107795B2 (en) 2012-10-25 2018-10-23 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US6372724B1 (en) * 1997-03-25 2002-04-16 Duska Scientific Co. Modulation of human mast cell activation

Also Published As

Publication number Publication date
JP2001518118A (ja) 2001-10-09
US6372724B1 (en) 2002-04-16
EP1011686A1 (en) 2000-06-28
AU7098598A (en) 1998-10-20
AU741713B2 (en) 2001-12-06
EP1011686B1 (en) 2010-06-09
WO1998042353A1 (en) 1998-10-01
US6465441B2 (en) 2002-10-15
EP1011686B9 (en) 2011-02-09
DE69841711D1 (de) 2010-07-22
CA2288821C (en) 2008-10-14
EP1011686A4 (en) 2003-03-19
CA2288821A1 (en) 1998-10-01
US20020055515A1 (en) 2002-05-09
ATE470441T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
DK1011686T3 (da) Modulering af human mastcelleaktivering
ATE510551T1 (de) Hemmung von gs-fdh zur modulierung der no- bioaktivität
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
BR0206985A (pt) Anticorpos modificados e métodos de uso
AU2002345500A1 (en) Sams modifiers of the p53 pathway and methods of use
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
WO2001083755A3 (en) Human anti-cd40 antibodies and methods of making and using same
BR0015110A (pt) Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
ATE419804T1 (de) Implantat
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
EA200500206A1 (ru) СПОСОБ И КОМПОЗИЦИИ ДЛЯ МОДУЛЯЦИИ РАЗВИТИЯ И ФУНКЦИИ КЛЕТОК Т-ХЕЛПЕРОВ (Тх)
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
MXPA03010634A (es) Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.
NO20052267L (no) Forbindelser, Preparater og Metoder
DE69125855D1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
DK1185621T3 (da) Overflade til cellekultur
ES2039578T3 (es) Procedimiento para producir mercapto-acilaminoacidos antihipertensivos.
WO2004053144A3 (en) Modulation of stem cell differentiation by modulation of caspase-3 activity
WO2002017900A9 (en) Modulators of us28 (chemokines) for treating cytomegalovirus infections
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren